May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on...
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$282.00 |
Change
0.660(0.23%) |
Mkt cap ! $136.2B | |||
| Open | High | Low | Value | Volume |
| $283.00 | $284.64 | $281.65 | $164.0M | 579.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3 | $282.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $282.02 | 469 | 2 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$282.49 |
Change
0.660 ( 0.53 %) |
||||
| Open | High | Low | Volume | ||
| $283.00 | $284.55 | $281.72 | 36821 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| CSL (ASX) Chart |